Targeting TGFβ sequestration to the tumor site may also reduce the potential adverse effects of using a systemic TGFβ inhibitor, such as cardiac toxicity, development of neoplasms, and re-activation of dormant cancer cells seen in preclinical models with some TGFβR-targeted small molecule inhibitors.23 Here, TGFB1 is linked to cancer.